Dermisonics, Inc. manufactures ultrasonic transdermal drug-delivery technologies and equipment. It primarily focuses on the development, testing, and commercialization of its active transdermal patch, called the U-Strip, that has been designed to facilitate the needle-free delivery of drugs with large molecular structures, such as Insulin into the bloodstream. The company was formerly known as Sec...
Dermisonics reported revenue of $0 for fiscal year 2006, and net income of -$5.08 million. In Q3 2007 (the quarter ended June 30, 2007) revenue was $0. Its market capitalization was $1,917 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended September 30, 2006; market data as of October 8, 2026.
No profile data available.